Connor Clark & Lunn Investment Management Ltd. Buys New Stake in Evolus, Inc. (NASDAQ:EOLS)

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 58,046 shares of the company’s stock, valued at approximately $940,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.09% of Evolus at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. lifted its holdings in shares of Evolus by 5,627.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Evolus by 24.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock worth $1,965,000 after buying an additional 35,760 shares in the last quarter. Armistice Capital LLC acquired a new position in Evolus in the 2nd quarter worth $3,906,000. California State Teachers Retirement System lifted its holdings in Evolus by 1.6% in the 1st quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock worth $674,000 after buying an additional 739 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Evolus by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock worth $559,000 after buying an additional 1,637 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on EOLS shares. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Barclays boosted their target price on shares of Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a research report on Monday, September 16th.

Evolus Trading Up 7.6 %

Shares of NASDAQ:EOLS opened at $13.80 on Thursday. The company has a 50 day moving average of $15.42 and a 200-day moving average of $13.86. The firm has a market cap of $873.82 million, a P/E ratio of -14.10 and a beta of 1.31. Evolus, Inc. has a twelve month low of $9.32 and a twelve month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Insider Transactions at Evolus

In related news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This represents a 2.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the sale, the chief marketing officer now owns 82,375 shares in the company, valued at $1,305,643.75. This represents a 6.40 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.